{
  "id": "Prostate_cancer_treatment_recommendation.v0",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2023-04-07",
      "name": "Rong Chen",
      "organisation": "Cambio Healthcare Systems",
      "email": "rong.chen@cambio.se"
    },
    "lifecycle_state": "Not set",
    "details": {
      "en": {
        "id": "en"
      }
    },
    "other_details": {}
  },
  "definition": {
    "data_bindings": {
      "gt0002": {
        "id": "gt0002",
        "model_id": "openEHR-EHR-EVALUATION.prostate_cancer_risk_group.v0",
        "template_id": "openEHR-EHR-EVALUATION.prostate_cancer_risk_group.v0",
        "type": "INPUT",
        "elements": {
          "gt0003": {
            "id": "gt0003",
            "path": "/data[at0001]/items[at0002]"
          }
        }
      },
      "gt0004": {
        "id": "gt0004",
        "model_id": "openEHR-EHR-EVALUATION.prostate_cancer_assessment.v0",
        "template_id": "openEHR-EHR-EVALUATION.prostate_cancer_assessment.v0",
        "type": "OUTPUT",
        "elements": {
          "gt0005": {
            "id": "gt0005",
            "path": "/data[at0001]/items[at0033]"
          }
        }
      },
      "gt0010": {
        "id": "gt0010",
        "model_id": "openEHR-EHR-EVALUATION.prostate_cancer_assessment.v0",
        "template_id": "openEHR-EHR-EVALUATION.prostate_cancer_assessment.v0",
        "type": "INPUT",
        "elements": {
          "gt0011": {
            "id": "gt0011",
            "path": "/data[at0001]/items[at0006]"
          },
          "gt0013": {
            "id": "gt0013",
            "path": "/data[at0001]/items[at0053]"
          }
        }
      }
    },
    "rules": {
      "gt0006": {
        "id": "gt0006",
        "priority": 8,
        "when": [
          "$gt0003|Risk group|==1|local::at0003|Very low risk|"
        ],
        "then": [
          "$gt0005|Recomendations|='Active monitoring is recommended if curative treatment could be relevant later.'"
        ]
      },
      "gt0007": {
        "id": "gt0007",
        "priority": 7,
        "when": [
          "$gt0003|Risk group|==2|local::at0004|low risk|"
        ],
        "then": [
          "$gt0005|Recomendations|='Men with more than 10-15 years of expected remaining life should primarily be recommended active monitoring. However, curative treatment should be considered for men with a long life expectancy and highly disseminated Gleason grade 3 cancer, as many of these men have a concurrent, undetected Gleason grade 4 cancer.'"
        ]
      },
      "gt0008": {
        "id": "gt0008",
        "priority": 6,
        "when": [
          "$gt0003|Risk group|==3|local::at0005|Intermediate risk|"
        ],
        "then": [
          "$gt0005|Recomendations|='Radiotherapy or radical prostatectomy is recommended for more than 10–15 years of life expectancy. Expectancy with possible later hormone treatment in the event of significant progress is recommended for less than 10–15 years of expected remaining life. Active monitoring is recommended if it is unclear whether curative treatment is warranted or not, e.g. at expected remaining life of about 10–15 years, and at very small findings of Gleason grade 4 in the absence of other prognostically unfavorable factors (palpable or visible tumor, high PSA density, cribriform pattern, intraductal cancer).'"
        ]
      },
      "gt0009": {
        "id": "gt0009",
        "priority": 5,
        "when": [
          "$gt0003|Risk group|==4|local::at0006|High risk|",
          "$gt0011|T - Primary Tumour|==local::at0011|T3|"
        ],
        "then": [
          "$gt0005|Recomendations|='Curatively aimed treatment is justified mainly for men with more than about 10 years of expected remaining life. T3: Radiotherapy in combination with hormone therapy. Primary hormonal treatment is recommended for patients with a life expectancy of more than 5 years who are not eligible for curative treatment, as well as for those with a shorter life expectancy who have symptoms of the cancer.'"
        ]
      },
      "gt0012": {
        "id": "gt0012",
        "priority": 4,
        "when": [
          "$gt0003|Risk group|==4|local::at0006|High risk|",
          "$gt0011|T - Primary Tumour|!=local::at0011|T3|",
          "$gt0011|T - Primary Tumour|!=local::at0012|T4|"
        ],
        "then": [
          "$gt0005|Recomendations|='Curatively aimed treatment is justified mainly for men with more than about 10 years of expected remaining life. T1-2: Radiotherapy in combination with hormone therapy and radical prostatectomy are judged to be equivalent at group level. Individual factors should guide the choice between them. Primary hormonal treatment is recommended for patients with a life expectancy of more than 5 years who are not eligible for curative treatment, as well as for those with a shorter life expectancy who have symptoms of the cancer.'"
        ]
      },
      "gt0014": {
        "id": "gt0014",
        "priority": 3,
        "when": [
          "$gt0003|Risk group|==5|local::at0007|Very high risk|",
          "$gt0011|T - Primary Tumour|!=local::at0011|T3|",
          "$gt0011|T - Primary Tumour|!=local::at0012|T4|"
        ],
        "then": [
          "$gt0005|Recomendations|='T1-2: Radiotherapy in combination with hormone therapy and radical prostatectomy are judged to be equivalent at group level. Individual factors should guide the choice. Primary hormonal treatment is recommended for patients with more than 5 years of expected remaining life who for some reason are not eligible for curative treatment, as well as for those with a shorter expected remaining life who have symptoms of the cancer. Expectancy is only recommended for asymptomatic patients with a very short expected remaining life.'"
        ]
      },
      "gt0015": {
        "id": "gt0015",
        "priority": 2,
        "when": [
          "$gt0003|Risk group|==5|local::at0007|Very high risk|",
          "($gt0011|T - Primary Tumour|==local::at0011|T3|)||($gt0011|T - Primary Tumour|==local::at0012|T4|)"
        ],
        "then": [
          "$gt0005|Recomendations|='T3-T4: Radiotherapy in combination with hormone therapy. Primary hormonal treatment is recommended for patients with more than 5 years of expected remaining life who for some reason are not eligible for curative treatment, as well as for those with a shorter expected remaining life who have symptoms of the cancer. Expectancy is only recommended for asymptomatic patients with a very short expected remaining life.'"
        ]
      },
      "gt0016": {
        "id": "gt0016",
        "priority": 1,
        "when": [
          "$gt0003|Risk group|==5|local::at0007|Very high risk|",
          "$gt0013|Total risk factors|>=2"
        ],
        "then": [
          "$gt0005|Recomendations|='Radiation therapy should be combined with hormonal therapy, including 2 years of abiraterone.'"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "Prostate cancer treatment recommendation"
          },
          "gt0003": {
            "id": "gt0003",
            "text": "Risk group",
            "description": "Risk group"
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Recomendations",
            "description": "Recomendations"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Very low risk group"
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Low risk group"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "Intermediate risk group"
          },
          "gt0009": {
            "id": "gt0009",
            "text": "High risk group 1"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "T - Primary Tumour",
            "description": "T - Primary Tumour"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "High risk group 2"
          },
          "gt0013": {
            "id": "gt0013",
            "text": "Total risk factors",
            "description": ""
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Very high risk group 1"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "Very high risk group 2"
          },
          "gt0016": {
            "id": "gt0016",
            "text": "Very high risk group 3"
          }
        }
      }
    }
  }
}